Patients with non-small cell lung cancer (NSCLC) receiving docetaxel (DTX) and ramucirumab (RAM) regimen frequently experience febrile neutropenia (FN).
We aimed to clarify the incidence rate and predictive factors of FN under prophylactic pegfilgrastim.
